Andrew P. Han

Editor

Phone Number

+1-212-651-5640

Email

[email protected]

Andrew Han covers breaking news for GenomeWeb. He tracks companies in the sequencing and diagnostic markets.

Articles Authored by Andrew P. Han

Jan 11, 2021

Illumina CEO Discusses Pan-Cancer IVD Assay, CDx Collaborations at JP Morgan

The firm also provided preliminary revenues of $950 million for Q4 and reinstated guidance of $3.79 billion to $3.88 billion for 2021.

Nov 24, 2020

Startup Angstrom Bio Plans Saliva-Based COVID-19 Nucleic Acid Test on Nanopore Sequencing Platform

Premium

Angstrom Bio is developing a rapid, scalable coronavirus test that uses nanopore sequencing to detect barcoded PCR products.

Nov 11, 2020

Adaptive Biotechnologies Prepares to Launch T Cell-Based COVID-19 Test

Premium

Adaptive is rebranding its immunoSeq Dx assay as T-Detect and plans to submit for an EUA for a COVID-19 T-Cell response test by the end of the year.

Sep 21, 2020

Grail Deal Will Enable Illumina to Expand From Tech Innovator to Diagnostics Provider

Premium

Illumina thinks the next-generation sequencing cancer testing market will grow to $75 billion over the next 15 years, driven by screening.

Aug 17, 2020

Bionano Genomics Expecting Clinical Validation Studies to Drive Platform Adoption

Premium

The firm is hoping that researcher-generated data will soon be published in peer-reviewed papers, while it weathers the COVID-19 pandemic.

Aug 07, 2020

Illumina Sees Expanding Sequencing Market in COVID-19 Response, Despite Short-Term Woes

Premium

The sequencing firm said infectious disease research, diagnostics, screening, and surveillance could all increase demand for its NGS products.

Aug 05, 2020

Fulgent Genetics Touts Returns on COVID-19 Testing Investment

Premium

Company officials credited investments in information technology, as well as R&D for RT-PCR-based tests, with driving up the firm's billable testing numbers.

Jun 26, 2020

Iowa Startup FBB Biomed Pursues RNA Blood Test to Predict COVID-19 Disease Severity

Premium

FBB Biomed, cofounded by a diagnostics industry veteran, is attempting to develop a blood RNA test to predict COVID-19 disease severity.

Jun 11, 2020

Avida Biomed Developing Hybridization-Based Methylation Sequencing Panels for Cancer Dx

Premium

The firm touts a new hybridization probe design, which it says will enable small, focused panels that reduce sequencing costs and assay time.

Jun 09, 2020

Judge Allows Whistleblower Suit Against Myriad Genetics to Proceed

Premium

In January a federal court unsealed a False Claims Act suit from an industry insider that alleges a Myriad subsidiary engaged in a fraudulent kickback scheme.

Menu

Andrew P. Han

Illumina CEO Discusses Pan-Cancer IVD Assay, CDx Collaborations at JP Morgan

Startup Angstrom Bio Plans Saliva-Based COVID-19 Nucleic Acid Test on Nanopore Sequencing Platform

Adaptive Biotechnologies Prepares to Launch T Cell-Based COVID-19 Test

Grail Deal Will Enable Illumina to Expand From Tech Innovator to Diagnostics Provider

Bionano Genomics Expecting Clinical Validation Studies to Drive Platform Adoption

Illumina Sees Expanding Sequencing Market in COVID-19 Response, Despite Short-Term Woes

Fulgent Genetics Touts Returns on COVID-19 Testing Investment

Iowa Startup FBB Biomed Pursues RNA Blood Test to Predict COVID-19 Disease Severity

Avida Biomed Developing Hybridization-Based Methylation Sequencing Panels for Cancer Dx

Judge Allows Whistleblower Suit Against Myriad Genetics to Proceed

Breaking News

Biden Unveils Economic Plan to Provide $50B for COVID-19 Testing Expansion

Report Details COVID-19 Testing Within Federal Government

In Brief This Week: Thermo Fisher, Yourgene Health, Deep Lens, and More

DARPA Awards $36.7M to Six Organizations for Gene Editing-Based Dx, Biosurveillance Tech

FDA Grants Emergency Use Authorization for SML Genetree Molecular Coronavirus Test

Invitae, Pharma Firms Partner to Develop Standard MRD Panel for AML Clinical Trials

Sponsorships